Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the advanced liver cancer market right now?

The market size of advanced liver cancer has experienced swift growth in the past few years. An increase from $1.89 billion in 2024 to $2.17 billion in 2025, with a compound annual growth rate (CAGR) of 15.2%, is expected. The prominent growth in the historic period is credited to a heightened awareness of liver cancer, a larger pool of patients, heightened demand for specialized therapies, improved healthcare infrastructure, and a rising demand for minimally invasive treatments.

How fast Is the advanced liver cancer market expected to grow, and what’s its future value?

Rapid escalation is anticipated in the advanced liver cancer market size in the forthcoming years, with a projected growth to $3.78 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. This projected growth during the forecasted period can be credited to factors such as the rising occurrence of liver cancer, an increase in healthcare expenditures, a heightened prevalence of genetic disorders, a growing preference for precision medicine, and a rise in the utilization of screening and diagnostic procedures. Noteworthy trends during this forecasted period encompass the incorporation of artificial intelligence in treatments, the invention of cutting-edge drugs and therapy, extended research and development activities, advancements in targeted therapy, and a surge in the demand for personalized medication.

Get your advanced liver cancer market report here!

https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer–global-market-report

What are the leading drivers of growth in the advanced liver cancer market?

The expected upswing in the advanced liver cancer market can be attributed to the rising prevalence of prolonged hepatitis infections. Prolonged viral infections, such as hepatitis, can last for over six months resulting in liver damage, cirrhosis, or liver cancer. The surge in such types of hepatitis infections can be traced back to insufficient screening and vaccination, as well as deferred treatment access. Chronic hepatitis B (HBV) or C (HCV) infections are noted as the prime reasons for cirrhosis and hepatocellular carcinoma (HCC), a dominant form of liver cancer. The persistence of these infections leads to liver inflammation and damage, and can cause cancer over time. As these infections continue to be widespread, more individuals become susceptible to advanced liver cancer. For example, the World Health Organization, a Switzerland-based intergovernmental organization, reported in April 2024 that in 2022, 254 million people were affected globally by chronic hepatitis B, recording 1.2 million new cases each year. Therefore, the increased prevalence of prolonged hepatitis infections stimulates the growth of the advanced liver cancer market.

What are the key segments defining the advanced liver cancer market?

The advanced liver cancer market covered in this report is segmented –

1) By Test Type: Imaging Test, Biopsy, Genomic Test, Other Test Types

2) By Technology: Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, Other Technologies

3) By Distribution Channel: Direct Tenders, Retail Sales, Other Distribution Channel

4) By Application: Screening, Diagnostic And Predictive, Prognostic, Research

5) By End-User: Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Imaging Test: Ultrasound, CT (Computed Tomography) Scan, MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) Scan

2) By Biopsy: Needle Biopsy, Laparoscopic Biopsy, Surgical Biopsy

3) By Genomic Test: Next-Generation Sequencing (NGS), PCR (Polymerase Chain Reaction) Testing, Genetic Mutation Profiling

4) By Other Test Types: Serum Biomarker Testing, Liver Function Tests, Alpha-Fetoprotein (AFP) Test, Elastography Tests

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp

Who are the key players steering the development of the advanced liver cancer market?

Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.

What are the key trends shaping the future of the advanced liver cancer market?

Leading firms in the advanced liver cancer market are concentrating on the development of groundbreaking drugs such as human monoclonal antibodies to enhance treatment effectiveness and reduce side effects, resulting in improved patient outcomes. Such an antibody is a laboratory-made molecule that mimics the immune system’s role in fighting off harmful pathogens or cancer cells, specifically targeting antigens on these harmful bodies to stimulate an immune response. For example, in October 2022, AstraZeneca, a pharmaceutical organization based in America, declared that the US Food and Drug Administration (FDA) endorsed Imjudo (tremelimumab) together with Imfinzi (durvalumab) for treating adult patients diagnosed with inoperable hepatocellular carcinoma (HCC), a predominant form of liver cancer. This approval was grounded on the outcomes of the HIMALAYA Phase III trial. This showed that this combination therapy diminished the death risk by 22% as compared to sorafenib, with about 31% of patients surviving after three years compared to the 20% on sorafenib. Known as STRIDE, this regimen involves an initial dose of Imjudo followed by consistent doses of Imfinzi every four weeks, thus providing a fresh treatment option for patients with limited treatment alternatives.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20706

Which regions are most influential in expanding the advanced liver cancer market?

North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Liver Cancer Diagnostics Global Market Report 2025

https://thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Buccal Drug Delivery System Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: